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Abstract 
This Work Project gives new insights into the liquidity and profitability relationship in 
the pharmaceutical industry, by adding epidemiological and economic variables to the debate. 
Between 2013 and 2017, the results show two significant relationships, positive in India, and 
negative in the United States (US). US producers are recommended to diversify and improve 
cost efficient processes, to decrease government dependency and increase customer reach. In 
Indian companies since working capital efficiency is a profitability driver, managers are 
recommended to sustain low production and skilled labour costs, and decrease cash conversion 
cycle and operating risk, while investing in marketing.  
Keywords: Liquidity; Profitability; Cash Conversion Cycle, India, United States. 
1. Introduction  
With lower production costs and increased acceptability, developing countries are a 
growing threat to the United States dominance in the pharmaceutical industry. In 2016, the 
United States (US) represented 30 to 40 percent of the global market (Ellis, 2016), with more 
than 15 top market capitalization companies in the industry. The Indian pharma market is 
recognizable worldwide, and leader in the generic drugs market (IBEF, 2018). Exports, which 
the main destination is the US, grew 2.92% from 2017 to 2018 (The Economic Times, 2018) 
and by 2020, India - which is part of BRICS1 and Tier II2 - is expected to be at the top three 
pharmaceutical markets by incremental development, and sixth by absolute size (IBEF, 2018).  
From 2007 to 2012, the compound annual growth rate (CAGR) was 5% (volume) for 
the total market and 8% for pharmerging markets. From 2012 to 2017, the overall market 
CAGR was 2%, while for pharmerging and developed nations it was, respectively, 4%, and 1%. 
                                                     
1 BRICS stand for Brazil, Russia, India, China, and South Africa. 
2 Tiers are grouped as follows: Tier I- China; Tier II- Russia, India & Brazil; Tier III- Argentina, Egypt, Indonesia, 
Mexico, Pakistan, Poland, Romania, South Africa, Thailand, Turkey, Ukraine, Venezuela, Vietnam. Pharmerging 
markets: simultaneously GDP < 30,000 USD and > 1Bn USD or LCUSD in absolute 5yr growth (2014-2019) 
(IQVIA, 2017).  
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Although pharmerging nations’ CAGR has decelerated, it is still higher than the CAGR in 
developed nations and the total market. From 2017 to 2022, the CAGR forecast is 3% on 
pharmerging markets, and null variation on developed markets (IQVIA, 2018).  
Pharmaceuticals’ main issue is sustaining financial performance and operating margins 
(Deloitte, 2018). Thus, liquidity and profitability play a role in the industry’s future 
development, by ensuring long-term growth. An adequate liquidity position prevents volatility 
in market oscillations, insolvency, and bankruptcy situations (Panigrahi, Raul & Chaitrali 
Gijare, 2017). Profitability ensures future operation (Mathuva, 2010).  
This research’s purpose is to understand how epidemiological and economic factors and 
products commercialized influence the liquidity and profitability relationship in the 
pharmaceutical industry in India and the US. Following the Introduction, Section 2 provides an 
overview of the pharmaceutical industry in the United States and India while highlighting the 
possible impact on key concepts. Section 3 reviews the empirical literature. Section 4 outlines 
the research questions, methodology, sample, and data. Section 5 presents, discusses the results 
and provides recommendations. Section 6 concludes and offers suggestions for future research. 
2. Key Concepts and Contextual Background 
The pharmaceutical industry incorporates all the processes involved in the manufacture, 
extraction, processing, purification, and packaging of chemicals used to medicate humans or 
animals. There are three types of pharmaceuticals marketed, branded ones, generics, and 
biosimilar.3 Branded pharmaceuticals include all the company’s pharmaceutical products that 
have held (or currently hold) official patents. Generics, on the contrary, have never held an 
exclusive official patent over a pharmaceutical. By having the same active ingredients, they 
work similarly and meet the same standards that branded pharmaceuticals have too. Biosimilars 
                                                     
3 See Annex 1 for a detailed description of each type of pharmaceuticals marketed. 
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are identical “copies” of another product produced by another company which approves them 
once the patent expires, and have never held exclusive patents to products.  
Profitability is a performance indicator that reflects the company’s capacity to generate 
revenues in excess to the expenses during a specific period. Some of the measures to access it 
are Return on Assets (ROA), Return on Equity (ROE), and Gross Sales Margins. ROA 
evidences how efficient the company is in using its assets to generate profits.  
𝑅𝑂𝐴 =
𝐸𝑎𝑟𝑛𝑖𝑛𝑔𝑠 𝐵𝑒𝑓𝑜𝑟𝑒 𝐼𝑛𝑡𝑒𝑟𝑒𝑠𝑡 𝑎𝑛𝑑 𝑇𝑎𝑥𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝐴𝑠𝑠𝑒𝑡𝑠
 [2] 
ROA may be split4 into Operational Risk (OR), Gross Sales Margin (GSM) and Asset 
Turnover (AT)5, as follows: 
𝑅𝑂𝐴 =
𝐸𝑎𝑟𝑛𝑖𝑛𝑔𝑠 𝐵𝑒𝑓𝑜𝑟𝑒 𝐼𝑛𝑡𝑒𝑟𝑒𝑠𝑡 𝑎𝑛𝑑 𝑇𝑎𝑥𝑒𝑠
𝐺𝑟𝑜𝑠𝑠 𝑀𝑎𝑟𝑔𝑖𝑛
×
𝐺𝑟𝑜𝑠𝑠 𝑀𝑎𝑟𝑔𝑖𝑛
𝑆𝑎𝑙𝑒𝑠
×
𝑆𝑎𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝐴𝑠𝑠𝑒𝑡𝑠
   [3] 
ROA highly depends on the industry6, consequently, comparing companies within an 
industry highlights differences and similarities in the operating context and managers’ strategic 
and operational decisions. During the spring season, usually due to pollination, individuals with 
allergies need to take special medication, and in autumn some population segments are advised 
to be vaccinated against the flu. These events spike sales without necessarily increasing total 
assets (TA) and reinforcing ROA’s seasonality dependency. Furthermore, during a recession, 
due to lower purchasing power, the choice may be to swap branded products for generics, 
increasing, therefore, the generics’ ROA while decreasing branded pharmaceuticals’ ROA.  
Liquidity acknowledges the extent to which a company is able to meet its current debt 
while taking advantage of its current assets, namely inventories, trade debts, and cash. Higher 
liquidity means better ability to face adversarial environmental conditions while maintaining a 
                                                     
4 Based on the DuPont method developed in the 1920s by DuPont de Nemours Corporation. 
5 See Annex 2 for definition of ROA, and its components. 
6 For example, a banks tend to hold higher levels of assets, which may be cash, investments, and loans. If a 
pharmaceutical company obtains similar EBITDA (while holding less totals assets) it will generate higher return 
on assets than the bank.  
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low financial risk of bankruptcy. Liquidity ratios, cash conversion cycle, and cash flow 
statement analysis are some of the liquidity measures. 
Ratios allow to compare companies of different size, and with financial statements 
expressed in different currencies. Liquidity ratios, such as the Current ratio (CR), the Quick 
ratio (QR), the Working capital turnover ratio (WC Turn), and the Inventory to net working 
capital ratio (Inv/WC)7 provide an understanding of the company’s ability to meet liabilities’ 
deadlines, and are particularly crucial to short-term creditors (Mathuva, 2010). Nonetheless, 
these ratios have inherent disadvantages. As Finnerty (1993) explains, operating assets, since 
involved in the operating cycle of the firm, should not be included in the analysis. Moreover, 
liquidity ratios are static in nature, with computations mainly based on balance sheet accounts, 
and, therefore, their predictive ability is limited (Kamath, 1989).  
Cash Conversion Cycle (CCC)8 measures the time in days taken to convert resources 
into cash receipts obtained from sales and is a dynamic working capital measure, focused on 
income statement accounts (Bolek, 2013). The CCC components are the Days Inventory 
Outstanding (DIO), Days Sales Outstanding (DSO), and Days Payable Outstanding (DPO). 
𝐶𝐶𝐶 = 𝐷𝐼𝑂 + 𝐷𝑆𝑂 − 𝐷𝑃𝑂 [1] 
The CCC recognizes how much credit length should be available for customers, how 
much and how long inventory should be hold, and how to manage the supplier’s payment 
period. According to Moss and Stine (1993), Uyar (2009), and Bhutto, Abbas, Rehman and 
Shah (2011), CCC is negatively correlated to firm size (proxied by total assets), i.e., larger firms 
tend to have smaller CCC. A lower CCC is often desirable as it indicates less dependency on 
external financing, resulting in lower interest paid, and higher profitability. Management is able 
to increase liquidity by shortening either the average collection period, or the inventory levels, 
                                                     
7 See Annex 3, for definition of liquidity ratios, and the most commonly used ones. 
8 See Annex 4 for definition of CCC, and its components. 
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reducing costs, and decreasing losses, damages, and obsolete products. Also by extending 
average payment period liquidity increases. On the other hand, a high DIO, contributing to 
higher CCC, is beneficial if supply has to match a sudden expansion in demand. The 
lack/significance and the sign of the impact that CCC has on profitability depends on the 
products or services commercialized, the industry, the companies’ size, and how organized the 
firm is. Both working capital analyses are limited, and companies should balance them.  
These key variables depend on country-specific factors, such as weather, economic and 
health care environment, regulations, epidemiological factors, as well as company-specific 
factors, such as vision, mission, the product offered, strategy, and functional policies. Tables 1 
and 2 compare, respectively, the strengths and weaknesses, and the opportunities and threats in 
the pharmaceutical industry in India and the United States. 
 
Table 1: Strengths and weaknesses in the pharmaceutical industry 
 
Strenghts Weaknesses
> Largest generics provider in the world (supplying 40% of the 
generics demand in the US).
> Poor sanitary conditions.
> Highly fragmented supplier market (low market 
concentration)
> Intense price competition and strict price regulations may be deteorating to 
the companies' finances.
> Non-original brands pharmaceuticals constitute the largest 
portion of total sales (75%).
> Lack of proper infrastructure, investment in sales force, marketing and 
commercial operations.
> Lower R&D, labour, and production costs.
>  Most of the pharmaceutical companies deal with liquidity issues due to 
inefficient working capital management. 
> Lower price of commercialized products.
> Largest pharmaceutical market in the world.
> Unproportionate increase in healthcare costs increase in comparison to 
insurance coverage.
> Companies with strong reputations and brand-equity that 
maintain solid finances. 
> Strong price and quality relations not deemed as enough to benefit patients.
> Originators constitute the largest portion of total sales 
(72.96%).
>High market concentration due to the entry barriers raised by the early 
entrants that leveraged on market share and  government regulations.
India
United States
7 
  
Table 2: Opportunities and threats in the pharmaceutical industry 
 
Taking into account the future expected losses of exclusivity, US companies, being in a 
more mature pharma market, require flexibility in the types of products offered (IQVIA, 2018). 
As so, more efficient manufacturing processes, that diminish the cost of goods sold, must be 
set without sacrificing the companies’ profitability. With a wider range of products at a lower 
price, US pharma companies would increase their market share, prevent further market 
entrances, and the take on by foreign companies. Diversely, Indian companies offering low 
prices and being inefficient at working capital management are facing liquidity issues. Since 
entry barriers are not as significant in India as in the US, there is a threat for existing companies 
of losing their already small market shares. Consequently, Indian pharma companies need to 
heavily invest in sales force, infrastructure, marketing, and commercial operations to expand 
customer reach and establish better supplier relationships to increase bargaining power. The 
liquidity and profitability concern in both countries raises the question about their relationship.  
3. Literature Review 
According to Nicholas (1991), liquidity management is only a company’s concern in 
crisis or close to bankruptcy situations. Sagner (2001) states that working capital is a safeguard 
for short-term providers while maintaining the return on equity (ROE). Bhunia and Khan (2011) 
also agree on the lack of impact that the liquidity position has on profitability. In contrast, Price, 
Opportunities Threats
> With losses of exclusivity expected, an increase in 
accessibility and acceptibity of the generics market may be 
due.
> If demand is not elastic enough, when prices decrease, revenue may 
decrease, leading to the decrease in profitability (measured by profitability 
ratios).
> Higher GDP per capita growth, induces and increase in 
disposable income and, therefore, in health care spending.
> If Indian companies have to sacrifice sustainable finances to match with 
supply with the increase in demand.
> With the improvement of sanitary conditions, some of the 
most widely spread diseases may be significantly reduced.
> If the US decides to heavily compete in the generics pharmaceutical market.
> In an optimist scenario CAGR is expected to be 17% until 
2020.
> If companies are not able to build sufficient financially sound operating 
models.
> In the base scenario, CAGR is expected to be 14.5% (market 
reach of 55 billion USD) (close 2nd next to the US, in volume).
> In a pessimist scenario CAGR is expected to be 10% until 
2020, which is still above the expected for Asia & Australasia 
(5%).
> The growth factors are acceptability (46%), accessibility 
(33%), and epidemiological factors (1%) .
> Population aging and increase in life expectancy. > Larges losses of exclusivity are expected (105 Billion USD).
> Strong customer demand. > Price level is expected to rise 2-5% in the next few years. 
> If large companies invest in generics' sales, revenue increase 
may be even more significant.
> Growth in developed countries is expected to slow. CAGR expected to be 
4.4% until 2020. 
> Environmental volatility due to the government dependancy.
United States
India
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Haddock, and Brock (2003) illustrate the possibility of having a strong long-term financial 
position while not being able to repay the debt obligations. Mathuva (2010)9 indicates a 
significant negative relationship between CCC and profitability (proxied by net operating 
profit), a negative relationship between profitability and average collection period, and a 
positive relationship between some CCC components (inventory conversion period and average 
payment period), and profitability. Shin and Soenen (1998), Delof (2003), Lazaridis and 
Tryfonidis (2006), and Raheman and Nasr (2007) found a negative correlation between CCC, 
its components, and the value created for shareholders in various countries, namely the US, 
Greece, Belgium, and Pakistan10. To maximize value the former authors’ encourage managers 
to decrease the number of days inventory, receivables, and payables, and the CCC. Eljelly 
(2004)11 found a negative relationship between CR (most impactful liquidity measure on 
profitability), cash gap, and profitability (net operating income). The cash gap significance 
depends on which is the intensive factor (labour is less, and capital is more impactful). The 
pharmaceutical industry is capital intensive, meaning that CCC has a significant impact on 
profitability. In the US, Gill, Bigger, and Marthur (2010), based on data from 2005 to 2007, 
show a negative relationship between profitability (gross operating profit) and number of days 
accounts receivables, meaning that a large collection period for accounts receivable may induce 
lower profitability and a positive relationship between profitability and CCC. No statistical 
evidence was found regarding the relationship between profitability and number of days 
accounts payables, and the number of days inventory.  
 In the pharmaceutical industry, Khan and Safiuddin (2016) found a positive correlation 
between liquidity and profitability12 emphasising, however, that liquidity does not necessarily 
                                                     
9 Mathuva (2010) used a sample of 30 firms listed in the Nairobi Stock Exchange. 
10 Shin and Soenen (1998) used a sample of 58,985 firms in the American market, Lazaridis and Tryfonidis (2006), 
a sample of 131 companies listed in Athens Stock Exchange, Delof (2003), 1009 large Belgian Firms, and 
Raheman and Nasr (2007), 94 Pakistan firms listed in Karachi Stock Exchange. 
11 Eljelly (2004) used 29 joint stock companies in the industrial, agriculture and services sector in Saudi Arabia. 
12 In two of the largest Indian companies: Cipla and Dr. Reddy’s Lab. 
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imply higher profit. Ofoegbu, Duru, and Onodugo (2016)13 research focus on the importance 
of efficient liquidity management on profitability and stresses a strong positive correlation 
between CR and profitability. Panigrahi, Raul, and Gijare (2017)14 demonstrate how a low (or 
negative) working capital to increase profitability and return on capital, may compromise the 
liquidity position of the firm, and ability to comply with current liabilities, a major concern to 
short-term creditors. Viswanathan, Palanisamy, and Mahesh (2016) 15 research displays a 
negative relationship between CCC (and components) and profitability. Although liquidity 
positions were satisfactory, solvency positions were not. To increase profitability, companies 
should decrease the conversion period for working capital components, and control the cost of 
sales and other operating expenses. Vijayalakshmi and Srividya (2015)16 found the impact of 
the independent variables (WC Turnover, Working capital/Net worth, Net working 
capital/Current liabilities) on net profit to be inconstant. The minimum R-square is 47.9%. 
Finally, Prasad and Lakshmi (2018)17 found cash to be between 7% and 23% of total assets, 
and firm size to be positively related to liquidity, which may be a result of sales, lower 
operational costs and reduced investments in comparison to medium or small companies.  
The profitability and liquidity relationship remains dubious, which may be due to the 
different maturity stages of the pharmaceutical markets. Moreover, the working capital 
strategies Indian companies should follow as to unleash its growth potential are yet to be settled. 
This Work Project aims at giving new insights into the relationship between liquidity (proxied 
by liquidity ratios, and CCC) and the operating profitability measured by the ROA ratio.  
 
 
                                                     
13 With a sample of three pharmaceutical companies quoted in Nigerians Stock Exchange. 
14 With a sample of five major companies in India, 
15 Using 10 large companies in India. 
16 Analysed 10 Indian companies listed on the BSE and National Stock Exchange of India. 
17 Based on a sample of 15 Indian pharmaceutical companies (accounting for 29.31% of total market capitalization 
of companies listed in BSE Health Care. 
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4.1 Research Questions and Model of Research 
As debated in section 3, the relationship between liquidity and profitability is not 
consensual. A high liquidity level encourages external financing independence, leading, in the 
long-run, to better performance, and sustainable growth. The contrasting analysis of United 
States pharmaceuticals and the pharmerging markets provides a better response as to why 
potential CAGR is higher on developing nations, and what are the recommended strategies to 
increase results in the global market.  
RQ 1. H0: Liquidity has a significant relationship with ROA. 
By taking advantage of the ratios’ properties, it is possible to compare companies such as 
Johnson & Johnson (US) and Torrent Pharmaceuticals (India). The liquidity ratios used are the 
CR, QR, Inv/WC, and WC Turn. ROA analysis is broken into OR, GSM, and AT.  
RQ 2. H0: CCC and components have a significant relationship with ROA. 
In section 3, no consensus has been reached with regarding the sign of the relationship between 
Cash Conversion Cycle and Profitability relationship, particularly in the pharmaceutical 
industry. For CCC, the proxies used are DIO, DSO, and DPO.  
RQ 3. H0: Company size has a significant relationship with liquidity. 
The largest companies in India and the US are selected, as they better illustrate market 
tendencies while dictating the response strategies to environmental conditions. Gill, Bigger and 
Mathur (2010) prove no significant relationship between firm size and gross operating profit 
ratio. In contrast, Raheman and Nasr (2007) show a positive relationship between company size 
and profitability. The aim is, therefore, to clarify how company size (measured by total sales of 
the year18) relates to liquidity and profitability. 
RQ 4. H0: Company size has a significant relationship with ROA. 
                                                     
18 Most appropriate measure of company size taking into consideration that Return on Assets is the proxy chosen 
to measure profitability. Total assets and the employee’s number are other possible proxies of company’s size.  
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The univariate analysis (section 4.3) joins descriptive statistics to recognise the two 
countries’ companies’ characteristics. The bivariate analysis (section 5) (with a chosen 90% 
confidence level), entailing linear regressions, is adopted to validate the hypothesis set in 4.1.  
𝑌𝑡 = 𝑎 + 𝑏𝑋𝑡 [4] 
Yt is the dependent variable, and Xt is the independent variable The regression 
coefficient b, exhibits “what”, “why”, and “how much” is the impact of the explanatory 
variable, and a, the intercept, reveals the weight of exogenous variables. The variables used and 
the expected regression signs are exposed in Table 3. 
Table 3. Variables and expected signs of the relationships 
 
 
4.2. Sample and Data 
Before the decision about countries to select for the analysis, an initial sample, 
comprising 54 large companies from Europe, the United States, and Asia, was taken. The 10 
Chinese companies were excluded due to lack of English reporting. Data was retrieved from 
consolidated annual reports and SEC filings available on the companies’ website. The periods 
under analysis ranges from 2013 until 2017. The year-end for India differs from the US, the 
former begins on the 1st of April and ends on the 31st of March of the following year. The 31st 
December of 2017 in Europe and US is compared to the 31st March of 2018 in India, the 31st 
December of 2016 in Europe and US is compared to the 31st March of 2017 in Asia, onwards.  
With the 44 companies remaining (European, United States, and Japan), and the year-end 
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assumption, the minimum and the maximum revenue for 2017 is, respectively, 511 and 76,450 
million USD. Total revenue for 2017 (and March 2018) was approximately 752,380 million 
USD, and the average is 17,100 USD19. This research is based on a sample compounded by the 
largest pharmaceutical companies in India and US. The US was chosen since it is the most 
significant pharma market in the world, and India, due its remarkable presence in the generics 
market (which are increasing in acceptability) as well as growth potential.  
The final sample combines 27 companies, 16 from the US and 11 from India. US 
companies follow the US Generally Accepted Accounting Principles (GAAP), and Indian 
companies follow the domestic IAS (Indian accounting standards) and Indian GAAP. Although 
both are similar to International Financial Reporting Standards (IFRS) issued by the 
International Accounting Standards Board (IASB), the main differences lie on the revenue 
recognition expense recognition, derivatives, liabilities, assets, business combinations, 
consolidation. In 2017, the final sample companies’ were able to generate 343,390 million USD 
in revenues, 18.55% higher than in 2013, and representing 45.64% of the total revenues of the 
initial sample20. For 2017, the average total revenue for the final sample is, approximately, 
12,718 million USD, 25.6% less than the initial sample. From 2013 to 2017, the minimum 
revenue increased by 43.83% and the minimum revenue (76,450 million USD (Johnson & 
Johnson) rose by 7.20%. Minority interest21 is integrated into total equity value22. The 
composition of the initial, final sample and exclusion reasons is provided in Appendix 1.  
 
 
                                                     
19 Using the currency rates in 31st March of the respective year for Asian companies. 
20 Using the conversion rates in 31st March of the respective year for Indian companies (See Annex 6 for conversion 
rates used). 
21 Minority interest (non-controlling interest): “Portion of equity (net assets) in a subsidiary not attributable, 
directly or indirectly, to a parent.” (Deloitte, 2018) 
22 data was not available with regards to inventory purchases, this variable was estimated using:  
Purchases𝑛 = Inventory𝑛 − Inventory𝑛−1 + Cost of Goods Sold𝑛 
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4.3. Univariate Analysis 
To characterize Indian and the US pharma companies, the maximum, minimum, the 
average, standard deviation and variation coefficient, for each variable is analysed.  
Average sales are considerably lower in India, around 9.37% of the US’s average sales, 
being the increasing significance of online pharmaceutical sales in the US one explaining factor. 
In India, from 2013 to 2017, Cost of Goods Sold/ Annual Sales fell by 15.85% to 26.66% 
(2017), while in the US it decreased by 1.95% to 23.29% in 2017. In India, this can be attributed 
to lower production and skilled labour costs and increased manufacturing processes efficiency. 
Figure 1. Average ROA on the Pharmaceutical Industry (2013-2017)  
 
The drop in India’s pharma companies’ ROA (7.25 percentage points), between 2013 
and 2017, resulted from the decline in OR (in 2017 26.14% less) and AT (in 2017 21.07% less). 
The GSM in India increased by 6.06%. In contrast, the US’s ROA has remained relatively 
stable, increasing by 1.01 percentage points (in comparison to 2013) and hitting its maximum 
of 9.21% in 2014. The growth factor was the decrease in operational risk (by 42.70%), 
associated with the increase in the OR ratio. The average AT decreased by 2.76%, indicating 
lower efficiency in the use of assets to generate sales. The gross sales margin in the US slightly 
decreased by 0.69% when comparing to 2017. Only in 2017 was the US capable of matching 
India’s operating profitability, India’s average ROA was 8.64%, and the US was 8.82%. 
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Figure 2. Average Liquidity Ratios in the Pharmaceutical Industry (2013-2017) 
 
WC Turn is the liquidity ratio with the most significant difference between countries 
(3.06 percentage points, 84.59% lower in the US). From 2013 to 2017, Indian companies’ Inv/ 
WC increased by 357.26%, being in 2017, 6.5 times more than the US’ ratio. Thus, India’s 
liquidity not only is lower than US’s liquidity but has also declined in the period of analysis. In 
2013 the QR, being 113.48% higher in the US had the highest difference between the two 
countries. Since 2013, India’s QR fell by 4.96%, reflecting a lower capability of meeting current 
financial obligations with available funds. According to Prasad and Lakshmi (2018), in India, 
cash usually is 7% and 23% of total assets. The results, however, indicate a Cash/Total Assets 
ratio of 5.36% in India, and 14.40% in the US, reinforcing a higher liquidity level in the US.23  
Figure 3. Average CCC in the Pharmaceutical Industry (2013-2017)
 
In 2017, the average DIO is the CCC component that differs the most between countries.  
In 2017, DIO in the US and India was, respectively, 204 and 370 days. Therefore, India has a 
                                                     
23 Although with similar results, the ratios’ volatility differ, Inv/WC with a Coefficient of Variation of 254.89% in 
India (2017) and 126.38% in the US (2017), and QR with a Coefficient of Variation of 35.74% in India (2017) 
and 53.51% in the US (2017).  
15 
  
lower ability to turn inventory into sales. The average DSO is fairly similar, 75 days in the US 
and 83 days in India. The average DPO is 224 days in India and 160 days in the US. Although 
with an increasing trend the United States’ average CCC has always been below the Indian one.  
In India, the decrease in liquidity and ROA indicates a positive relationship between these 
variables. In the US, the match between the ROA increase and liquidity decrease illustrates that 
if significant, the relationship has a negative sign. Since similar ROA may be achieved through 
different combinations of OR, GSM, and AT, companies may balance these depending on the 
subjected conditions. The following sections answer the questions purposed in section 4.1. 
5.1. Relationship between Liquidity and Return on Assets  
In the US, CR has a significant negative correlation of -0.265 with OR (p-
value=1.7595%) and a significant positive relationship with GSM (p-value=0.0029%, 
correlation=0.449). AT does not have a significant relationship with CR (p-value=30.40%).  
The final result is a significant negative relationship between CR and ROA (p-value= 10.18%, 
R-square=3.40%)24. A one unit increase in the current ratio is expected to decrease ROA by 
1.5692%, ceteris paribus. The Indian companies express no significant relationship between 
CR and OR, nor with GSM. However, there is a significant relationship between CR and AT 
(p-value=3.1436%, b =0.107). CR and ROA have a significant positive relationship (p-
value=8.0507%) in India, aligning with Khan and Safiuddin (2016). 
In the US, there is a significant negative relationship between QR and OR (p-
value=1.3067%, b =-0.079), matching the relationship between CR and OR. There is also a 
significant positive relationship between GSM and QR (p-value=0.0002%, correlation=0.503). 
Similarly to CR, QR and AT do not have a significant relationship. A significant correlation of 
-0.194 is present between QR and ROA (p-value=8.5202%, b =-0.017). The Indian companies 
showed no relationship between the quick ratio, and return on assets, nor its components.  
                                                     
24 Considered as being a significant relationship due to the proximity to the 10% not included in the confidence 
interval. 
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In the United States, WC turn has a significant positive correlation of 0.204 with OR 
(p-value=6.9523%, R-square=4.16%). The regression coefficient is 0.032. There is also a 
significant negative relationship with GSM (p-value=0.0006%, b =-0.030). Neither AT nor 
ROA have a significant relationship with this liquidity ratio. In India, the WC Turn does not 
have a significant relationship with ROA, nor its components.  
In the US, Inv/WC only has a significant correlation of -0.583 with GSM (p-
value=0.000001%). Each unit change in the Inv/WC is expected to generate a decrease in GSM 
by 0.188 units, ceteris paribus. No significant relationships are established between this 
liquidity ratio and ROA, the remaining components. In India, no significant relationship is 
found between the Inv/WC and the profitability ratios (ROA and components). 
Table 4. Liquidity Ratios and Profitability’s relationship in India and United States
 
In both countries, there is a significant relationship between CR and ROA. In the US 
when CR increases, ROA decreases, meaning that the increase in Total Assets generated 
surpasses the increase in earnings (due to the expenses’ increase). In contrast, in India, when 
CR increases, ROA increases, meaning that these companies can increase liquidity while 
OR GSM AT ROA OR GSM AT ROA
p-value 1.7595% 0.0029% 30.4038% 10.1789% p-value 47.3547% 17.5700% 3.1436% 8.0507%
Coefficient -7.4013% 4.9757% -1.0730% -1.5692% Coefficient -2.2491% -2.5332% 10.6799% 2.5048%
Coefficient Sign - + - - Coefficient Sign - - + +
Significant a a r a Significant r r a a
Equal sign = Equal sign =
Equal significance = Equal significance =
p-value 1.3067% 0.0002% 52.2245% 8.5202% p-value 80.6241% 90.5449% 91.8169% 24.9686%
Coefficient -7.8896% 5.6887% -0.6837% -1.6844% Coefficient 0.9510% 0.2763% -0.6427% 2.0507%
Coefficient Sign - + - - Coefficient Sign + + - +
Significant a a r a Significant r r r r
Equal sign = = Equal sign = =
Equal significance = Equal significance =
p-value 33.6486% 0.0000% 50.6917% 99.5977% p-value 43.2941% 52.1984% 76.2479% 63.0908%
Coefficient 8.8800% -18.8348% -2.0265% 0.0142% Coefficient -0.3221% 0.1579% -0.2007% -0.0914%
Coefficient Sign + - - + Coefficient Sign - + - -
Significant r a r r Significant r r r r
Equal sign = Equal sign =
Equal significance = = = Equal significance = = =
p-value 6.9523% 0.0006% 55.0190% 29.6697% p-value 16.3769% 49.4040% 87.9447% 66.2635%
Coefficient 3.1933% -2.9798% 0.3502% 0.5634% Coefficient -0.1824% 0.0541% 0.0323% -0.0266%
Coefficient Sign + - + + Coefficient Sign - + + -
Significant a a r r Significant r r r r
Equal sign = Equal sign =
Equal significance = = Equal significance = =
CR
QR
Inv/WC
WC Turn
CR
QR
Inv/WC
WC Turn
United States India
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increasing revenues more than expenses and TA. In the United States, when liquidity increases 
GSM is expected to increase. In India, no consensus was found regarding the relationship 
between liquidity ratios and profitability ratios. In India and the US, the Inv/WC and WC Turn 
ratios had the highest Variation Coefficients among the sampled companies, explaining the lack 
of significant relationships with profitability variables25.  
5.2. Relationship between Cash Conversion Cycle and Return on Assets  
In the US there is a significant positive relationship between DIO and GSM (p-
value=0.5179%). When DIO increases by one day, the GSM is expected to increase by 
0.0328%, ceteris paribus. DIO is also negatively related to AT (p-value=0.0001%, b =-
0.045%). There is no significant relationship between DIO and OR, and DIO and ROA. Indian 
companies have a positive relationship between DIO and GSM (p-value=0.0004%, b =-
0.0434%). However, DIO has no significant relationship with the other ROA components.  
In the US, when DSO by one day, OR is expected to increase by 0.302%, ceteris paribus 
(p-value=1.3710%, correlation=0.275). Although there is no significant relationship with GSM 
nor AT, there is a significant positive relationship with ROA (p-value=0.30%, b =0.1097%). 
Indian pharma companies show no significant relationship with ROA, nor its components.  
The US pharmaceutical companies’ DPO does not have a significant relationship with 
AT. DPO and OR have a negative correlation of -0.188 (p-value=9.5406%). The impact of a 
day change on the OR is fairly low (b =-0.0072%). DPO and GSM are positively correlated by 
0.329 (p-value=0.28%, b =0.005%). Finally, there is a significant negative relationship with 
ROA (p-value=6.92%). The negative coefficient (-0.0024%) could be related to the fact that as 
the average accounts payable increase, relationships with suppliers and creditors may be 
damaged and future credit terms compromised. In India, DPO has only a significant correlation 
                                                     
25 Inv/WC not found to be significantly related to OR, AT, nor ROA, WC Turn was not found to be significantly 
related to AT and ROA. 
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with GSM (0.403) (p-value=0.23%). Despite having the same positive sign as the US, the 
magnitude of the impact on GSM is 0.027%, 0.022 percentage points, and 447% higher.  
In the US, there is a significant negative relationship between CCC and GSM (p-
value=1.0965%). The correlation is -0.283, and it matches the -0.0043% decrease in GSM if 
DPO increases by a day. No significant relationship is present with AT, and OR. Despite having 
a significant relationship with ROA (p-value=7.8064%), the correlation, the regression 
coefficient, and R-square are fairly low, respectively 0.198, 0.0023%, and 3.93%. In India, CCC 
is only significantly related to OR (p-value=2.242%, b =-0.034%), meaning that a higher CCC 
level translates into an increase in risk (OR decrease). 
Table 5. Cash Conversion Cycle and Profitability’s relationship in India and the United States 
 
Similarly to 5.1, in the US, liquidity, now measured by CCC, is negatively related to 
ROA, that is, when CCC increases ROA is expected to increase. The presence of low inventory 
levels reduces costs, losses, and damages. In order to increase profitability, US companies 
should increase the clients’ credit period and decrease the number of days payable. In India, 
CCC does not have a significant relationship with ROA. In both countries there is the positive 
relationship between DPO and GSM. A higher DPO, associated to higher supplier credit and 
better ability to negotiate prices, leads to lower cost of goods sold. This is particularly important 
OR GSM AT ROA OR GSM AT ROA
p-value 14.0588% 0.5179% 0.0001% 32.4673% p-value 15.5819% 0.0004% 47.2693% 42.1437%
Coefficient -0.0444% 0.0328% -0.0453% -0.0091% Coefficient -0.0243% 0.0434% 0.0200% 0.0064%
Coefficient Sign - + - - Coefficient Sign - + + +
Significant r a a r Significant r a r r
Equal sign = = Equal sign = =
Equal significance = = = Equal significance = = =
p-value 1.3710% 96.3734% 51.0585% 0.3001% p-value 14.3737% 98.4875% 19.8304% 54.1010%
Coefficient 0.3017% -0.0022% -0.0271% 0.1097% Coefficient -0.1177% -0.0009% 0.1675% 0.0229%
Coefficient Sign + - - + Coefficient Sign - - + +
Significant a r r a Significant r r r r
Equal sign = = Equal sign = =
Equal significance = = Equal significance = =
p-value 9.5406% 0.2849% 80.1402% 6.9241% p-value 45.1530% 0.2270% 51.1260% 14.3474%
Coefficient -0.0072% 0.0050% -0.0004% -0.0024% Coefficient 0.0117% 0.0274% -0.0165% 0.0104%
Coefficient Sign - + - - Coefficient Sign + + - +
Significant a a r a Significant r a r r
Equal sign = = Equal sign = =
Equal significance = = Equal significance = =
p-value 12.6716% 1.0965% 67.5560% 7.8064% p-value 2.2423% 41.0380% 12.9354% 55.4291%
Coefficient 0.0066% -0.0043% -0.0006% 0.0023% Coefficient -0.0337% 0.0075% 0.0366% -0.0041%
Coefficient Sign + - - + Coefficient Sign - + + -
Significant r a r a Significant a r r r
Equal sign Equal sign
Equal significance = Equal significance =
United States India
DIO DIO
DSO DSO
DPO DPO
CCC CCC
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during economic recessions, such as the US recession in 2008, and to emerging markets, such 
as the Indian pharmerging market.  
5.3. Company size and Liquidity and Profitability Relationship 
The US companies have a significant negative relationship between annual sales and 
CR (p-value=0.0009%). Annual sales have also a significant negative relationship with QR (p-
value=0.0015%, b =-0.0028%). WC Turn, on the other hand, has a significant positive 
relationship with annual sales (p-value=0.686%, b =0.0033%). The correlation of this 
regression is 0.300, so, in absolute value it is lower than the correlation of the other two liquidity 
ratios, which is expected since annual sales increase by more than working capital. With 
Inv/WC there is not significant relationship. In India there is no evidence of a significant 
relationships between annual size and the liquidity ratios. Inv/WC is the most volatile liquidity 
measure in the considered period. Furthermore, the analysis considered the largest 
pharmaceuticals companies in the India and the US. These play a role in the lack of significant 
relationship between company size and Inv/WC. In the US, using the other liquidity measures 
it is accessed that as company size increases liquidity is expected to decrease. In both countries 
the results do not align with Prasad and Lakshimi (2018) findings, but prove the possibility set 
out by Price, Haddock, and Brock (2003). 
In the US, annual sales are significantly positively correlated to OR (p-value=3.406%, 
b =0.0004%). In contrast, annual sales has a significant negative GSM (p-value=1.8082%). 
Since gross margin does not increase in the same proportion as the annual sales, the negative 
of this coefficient (-0.00018%) is expected. In the US pharmaceutical industry, company size 
is not significantly related with AT nor ROA. In India, there is a significant positive relationship 
between company size and GSM (p-value= 0.1069%, b =0.0033%). In contrast to the US, GSM 
increase as a result of the lower cost of goods sold/ annual sales, which has decreased 15.85% 
in comparison to 2013. These results match Gill, Bigger and Marthur (2010) research.  
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Table 6. Liquidity ratios and Profitability Proxies’ relationship with Company Size 
 
 
5.4. Recommendations 
With losses of exclusivity expected and increased acceptability of generics, United 
States pharmaceutical companies should diversify the portfolio of products offered, namely by 
extending to the generic drugs market while investing in cost-efficient manufacturing processes  
to lower prices. However, to decrease the cost of goods sold/ annual sales ratio and increase 
GSM, the price fall should not surpass the unit cost decrease.   As healthcare cost decreases, 
customer demand increases and the gap with supply diminishes. This would allow less 
dependency on government regulations and lead to an operational risk decrease (OR increase). 
Price on branded pharmaceuticals could be maintained or even increased since there would 
always be demand for the type, particularly in rich countries, and the effect on the non-branded 
pharmaceuticals would be enough to sustain the stable finances companies have built. This 
would mitigate the expected CAGR slowdown in the developed countries pharmaceutical’s 
market. Taking into consideration the strong reputations and bargaining power over suppliers, 
the effect of liquidity on profitability is no longer as significant.  
Most of the Indian pharmaceutical companies deal with liquidity issues due to 
inefficient working capital management. The financial instability associated with market and 
economic volatility marks the importance of maintaining a low CCC to decrease risk (increase 
OR ratio). By joining the better accessibility with the investment in Salesforce and marketing, 
CR QR WC Turn Inv/WC CR QR WC Turn Inv/WC
p-value 0.0009% 0.0015% 0.6862% 17.1966% p-value 26.6037% 11.4488% 55.1825% 51.7824%
Coefficient -0.0030% -0.0028% 0.0033% 0.0003% Coefficient 0.0085% 0.0097% -0.1081% -0.0377%
Coefficient Sign - - + + Coefficient Sign + + - -
Significant a a a r Significant r r r r
Equal sign Equal sign
Equal significance = Equal significance =
Annual Sales
United States India
Annual Sales
OR GSM AT ROA OR GSM AT ROA
p-value 3.4062% 1.8082% 80.9774% 10.8962% p-value 57.1049% 0.1069% 99.4044% 61.4665%
Coefficient 0.0004% -0.0002% 0.0000% 0.0001% Coefficient -0.0010% 0.0033% 0.0000% 0.0004%
Coefficient Sign + - + + Coefficient Sign - + - +
Significant a a r r Significant r a r r
Equal sign = Equal sign =
Equal significance = = = Equal significance = = =
United States India
Annual Sales Annual Sales
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to increase acceptability, customer demand is expected to increase. With higher market share, 
and stronger finances Indian companies can increase supplier bargaining power and the average 
payment period. Even with lower prices, by sustaining a low production and skilled labour cost 
they are able to rise average inventory to supply in a sudden expand demand situation, without 
spiking the low cost of goods sold/ annual sales ratio, nor sacrificing finances. Moreover, the 
barriers of entry are expected to raise due to the sales force, marketing, and cost efficiency 
investments new companies would need to support. Therefore, the increase in DPO and DIO 
induces the increase in GSM. Although the effect of DIO on GSM is similar positive in both 
countries, it is stronger in India. Finally, an improved working capital management, with higher 
liquidity, provides less volatility in adverse environments and leads to an increase in the ROA. 
6. Conclusion 
This research aimed to understand the liquidity and profitability relationship, and how 
epidemiological and economic factors influence it. The countries analysed were India and the 
United States, and the period of analysis ranges from 2013 to 2017. In both countries, there is 
a significant relationship between liquidity and profitability. In the US, when liquidity (liquidity 
ratios and CCC) increased return on assets decreased; this is possibly due to the matured market 
mainly composed of companies with strong brand-equity and bargaining power companies. In 
India, higher ROA is achieved through higher liquidity levels. Although in India Cash 
Conversion Cycle does not have a direct influence on ROA, maintaining it at a low level is vital 
to decrease operational risk. The early maturity stage and the unclear distinction between local 
players and multinational companies may justify the non-consensus around the possible 
relationships with company size. 
In India, the positive relationship between liquidity and ROA reveals the importance of 
increasing working capital efficiency. Managers should evoke new market opportunities, such 
as patents, public health, and vaccines, while establishing collaborations with stakeholders, seek 
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a balance between liquidity position and profitability rates, and improve companies’ 
organization. For market leadership, investment in salesforce, commercial operations, as well 
as marketing, is recommended there. In the US, exclusivity losses are expected, managers 
should leverage on the companies’ market positioning to diversify the portfolio of products 
offered, namely by extending to the generics market. With the costs efficient processes 
investment, they could be able to lower prices, without sacrificing product margins, particularly 
with elastic demand. Ultimately, this would increase customer reach and boost revenues.  
There were some limitations encountered in the research. Firstly, it considers distinct 
fiscal years (1st January till 31st December and 1st April till 31st March) meaning that external 
variables, such as environmental conditions, government policies (specific to that particular 
period) and seasonality, may slightly bias the analysis. Moreover, the fact that financial 
reporting standards in use differ in the two countries may exert an impact on the final results.  
This research only extends to the US and India pharmaceuticals markets. However, with 
the accelerated growth in the pharmerging markets it would be interesting to explore the Tier I 
has and is expected to progress in the following years while addressing the liquidity role. The 
forecast future branded and generics’ revenues based on the previous years’ evolution as well 
as the impact of the different financial reporting regulations are also topic left as suggestions 
for future research. 
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Appendix 1. Initial and Final Sample with exclusion criteria
 
Companies Country Exclusion Reasons
 Johnson & Johnson United States
 Pfizer United States
 AbbVie United States
Merck & Co. United States
 Amgen United States Biotechnology Company
 Bristol-Myers Squibb United States
 Abbott Laboratories United States
 Gilead Sciences United States Biotechnology Company
 Eli Lilly & Co United States
 Celgene United States Biotechnology Company
Biogen United States
 Stryker Corporation United States
 Regeneron Pharmaceuticals Inc United States
 Illumina United States
 Vertex Pharmaceuticals United States
 Zoetis United States Animals Pharmaceutical
 Mylan United States
 Alexion Pharmaceuticals United States
 BioMarin United States
 Incyte United States
Sun Pharmaceutical India
Lupin Ltd India
Dr. Reddy's Laboratories India
Cipla India
Aurobindo Pharma India
Zydus Cadila Healthcare India
Piramal Enterprises India
Glenmark Pharmaceuticals India
Torrent Pharmaceuticals India
Alkem Laboratories India 2012 non available accounts
Biocon Ltd. India
Ipca Laboratories India
Shangai Pharmaceuticals China Non available English reports
Sinopharm Group China Non available English reports
Jiangsu Hengrui Medicine China Non available English reports
Shangai Fosun Pharmaceuticals China Non available English reports
Huadong Medicine China Non available English reports
Yunnan Baiyao Group China Non available English reports
Guangzou Pharmaceutical China Non available English reports
Harbin Pharmaceutical China Non available English reports
China Meheco China Non available English reports
Kangmei Pharmaceutical China Non available English reports
 Roche Switzerland Non US/India
 Novartis Switzerland Non US/India
 Novo Nordisk Denmark Non US/India
 Sanofi France Non US/India
 Bayer Germany Non US/ India; Biotechnoly company
GlaxoSmithKline United Kingdom Non US/India
AstraZeneca United Kingdom Non US/India
 Allergan Ireland Non US/India
 Shire Pharmaceuticals Ireland Non US/India
  Takeda Pharmaceutical Japan Non US/India
 Astellas Japan Non US/India
 Daiichi Sankyo Japan Non US/India
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Supplementary Annexes:  
This section incorporates all the supplementary annexes indicated throughout the main text that 
not mandatory to understand the thesis. 
Annex 1: Types of pharmaceuticals marketed description 
Branded pharmaceuticals include all the company’s pharmaceutical products that have held (or 
currently hold) official patents. In other words, they hold exclusive right of producing or 
marketing it. Moreover, they tend to lever mainly on company’s reputation, knowledge, and 
endorsements by professionals and hospitals. The four categories it incorporates are biologics, 
emerging therapies, small molecules, and vaccines.  
Generics have never held exclusive official patent over a pharmaceutical. By having the same 
active ingredients, they work similarly and meet the same standards that branded 
pharmaceuticals have too. Meanwhile, due to the lack of inherent branding, they are less 
expensive than Branded pharmaceuticals.  
Biosimilars are identical “copies” of another product produced by another company. Similarly 
to generics, they have never held exclusive patents to products. They can only be produced once 
the patent expires and are approved by the original producer company. Consequently, although 
having higher levels of profitability, they have a riskier profile than generics as well as lower 
development costs and pipeline failure than branded products. 
Annex 2: Profitability Definitions 
The measure of profitability chosen is the Return on Assets (ROA). ROA shows how efficient 
is the company in converting its assets into earnings, and it is commonly used to compare 
companies within the same industry. A higher ROA is the companies’ objective. Through the 
DuPont decomposition method ROA is split into three components: Operational Risk, Gross 
Sales Margin, and Asset Turnover. 
𝑅𝑂𝐴 =
𝐸𝐵𝐼𝑇
𝑇𝑜𝑡𝑎𝑙 𝐴𝑠𝑠𝑒𝑡𝑠
⟺  𝑅𝑂𝐴 = 𝑂𝑅 × 𝐺𝑆𝑀 × 𝐴𝑇 
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Operational Risk (OR) is a measure of leverage incurred during the company’s operations, and 
accesses the fixed costs effect. The decrease in this ratio is associated to higher risk and lower 
ROA.  
𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑅𝑖𝑠𝑘 =
𝐸𝐵𝐼𝑇
𝐸𝐵𝐼𝑇𝐷𝐴
 
Gross Sales Margin (GSM) is a measure of how much of the sales generated is the company 
able to absorb. A higher GSM indicates that the company is profitable in its sales. 
𝐺𝑟𝑜𝑠𝑠 𝑆𝑎𝑙𝑒𝑠 𝑀𝑎𝑟𝑔𝑖𝑛 =
𝑆𝑎𝑙𝑒𝑠 − 𝐶𝑂𝐺𝑆
𝑆𝑎𝑙𝑒𝑠
 
Asset Turnover (AT) is a measure of the efficiency of the company in converting assets into 
revenue. A higher ratio means that the company is able to generate a certain level of revenue 
without requiring a high level of assets. 
𝐴𝑠𝑠𝑒𝑡 𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟 =
𝑆𝑎𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝐴𝑠𝑠𝑒𝑡𝑠
 
Annex 3: Liquidity Ratios Definitions 
Liquidity Ratios are financial measures to evaluate the company’s ability to meet its current 
liabilities. They not allow for comparisons between companies of different sizes and currencies, 
they simplify accounting statements, and help managers understand the impact of the decisions 
made relatively to the previous period. The most commonly used liquidity ratios are the 
currency ratio, quick ratio, inventory to net working capital ratio, and working capital ratio.  
The Current Ratio exposes to which extent the company is able to meet its current liabilities 
with its current assets. Current Ratios below 1 indicate that the company may incur problems 
in repaying its liabilities. High current ratios may indicate lack of efficiency in the use of current 
assets. Ultimately, the current ratio adopted may also depend on the industry concerned26. 
𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝑅𝑎𝑡𝑖𝑜 =
𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝐴𝑠𝑠𝑒𝑡𝑠
𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝐿𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠
 
                                                     
26 For instance, airline companies tend to have current ratios below 1. 
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The Quick Ratio, the Acid Test Ratio, also seeks to understand how the company is able to take 
advantage of its current assets to pay its debtors. However, it does not consider inventories to 
be readily transformed into cash, therefore, deducting it from the current assets sum. Hence, the 
quick ratio, may be regarded as a more conservative approach.  
𝑄𝑢𝑖𝑐𝑘 𝑅𝑎𝑡𝑖𝑜 =
𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝐴𝑠𝑠𝑒𝑡𝑠 − 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑖𝑒𝑠
𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝐿𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠
 
The Working Capital Turnover Ratio is a measure of working capital effectiveness, exploring 
the relationship between the company’s resources and its revenues. Generally, higher ratio 
indicates more effectiveness in working capital management, without much need of additional 
funding. However, if the working capital ratio assumes a value that is extremely high, it may 
be an indication that the company is unable sustain sales out of its capital, and in the near future 
it may incur insolvency issues27. 
𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝐶𝑎𝑝𝑖𝑡𝑎𝑙 𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟 𝑅𝑎𝑡𝑖𝑜 =
𝐴𝑛𝑛𝑢𝑎𝑙 𝑆𝑎𝑙𝑒𝑠
𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝐶𝑎𝑝𝑖𝑡𝑎𝑙
 
The Inventory to Net Working Capital Ratio shows how a company is able to finance its 
inventories based on the readily available funds. Typically, more specifically for companies 
that hold higher levels of inventory, a low ratio indicates higher liquidity. Similarly, they 
majorly diverge depending on the industry concerned.  
𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑡𝑜 𝑁𝑒𝑡 𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝐶𝑎𝑝𝑖𝑡𝑎𝑙 𝑅𝑎𝑡𝑖𝑜 =
𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦
𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝐶𝑎𝑝𝑖𝑡𝑎𝑙
 
Annex 4: Cash Conversion Cycle Definitions 
The Cash Conversion Cycle, also known as Cash Gap, measures the time in days it takes for a 
company to convert the resources invested into cash receipts obtained from sales of products or 
services provided. It is, therefore, used to analyse different working capital management 
strategies. Usually, a higher CCC is correlated to poor working capital management, and 
                                                     
27 When due the company is not able to meet its debt obligations. 
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consequently, companies look to decrease the CCC period. The cash conversion cycle may be 
decomposed in three segments: 
𝐶𝐶𝐶 = 𝐷𝐼𝑂 + 𝐷𝑆𝑂 − 𝐷𝑃𝑂 
In order increase working capital efficiency companies should not only aim to control one of 
the components (often the final effects do not align with the management goals). Accordingly, 
the goal is to manage a balance between the three variables. 
Days Inventory Outstanding (DIO) measures the time length, in days, the company holds its 
inventory before being able to generate sales from it. Therefore, a lower DIO is associated with 
shorter period to turn inventory into sales, and, thereby, higher liquidity. Although desirable, 
DIO are more attainable in cases where demand has a predictable nature, and it is highly 
correlated to seasonality (for instance, flu vaccines). In that case, working capital management 
adjusts to suit the consumer needs, without the need of holding excessive inventory that may 
be perishable after a long term.  
𝐷𝐼𝑂 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑖𝑒𝑠 
𝐶𝑂𝐺𝑆
× 365 
Days Sales Outstanding (DSO) measures the time length, in days, between the sale and the 
moment that the company receives its payment. It is also used as a measure of customer 
satisfaction. Hence, typically companies seek to decrease their DSO. This may be achieved 
through early payment incentives, such as exclusive discounts or bundle discounts, and by 
widening its payment methods’ range.  
𝐷𝑆𝑂 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑐𝑐𝑜𝑢𝑛𝑡𝑠 𝑅𝑒𝑐𝑒𝑖𝑣𝑎𝑏𝑙𝑒
𝐴𝑛𝑛𝑢𝑎𝑙 𝑆𝑎𝑙𝑒𝑠
× 365 
Days Payable Outstanding (DPO) measures the time length it takes for the company to repay 
its debtors. In common circumstances, companies seek to increase their DPO, which may be 
attained through better relationships with suppliers or renegotiations, as when sustaining the 
cash, they are able to increase revenues. 
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𝐷𝑃𝑂 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑐𝑐𝑜𝑢𝑛𝑡𝑠 𝑃𝑎𝑦𝑎𝑏𝑙𝑒
𝐴𝑛𝑛𝑢𝑎𝑙 𝑆𝑎𝑙𝑒𝑠
× 365 
Annex 5: Description of the India and the United States Pharmaceutical Markets 
Sun Pharma (Indian Company) was considered to be the 4th highest value generic 
pharmaceuticals companies worldwide in 2016, Pfizer Established Pharma (US company) was 
the one with the highest estimated value (Statista, 2016). Currently, India is the largest generic 
provider in the world, supplying approximately 40% of the demand of generics in the US. In 
2014, Generics were 76.15% of the Indian sales and originators were 9.85% (IPFMA, 2017). 
According to IQVIA (2018), by 2020 Indian pharmaceutical spending is expected to be split 
into: 15% original brands, 75% non-original brands, 7% other, and 3% unbranded. This 
pharmaceutical market has low concentration, with prices competition to gain market share. In 
the US, in 2014, originators constituted 72.96% of the total sales and generics constituted 
21.14% (IPFMA, 2017). The early entrance and patents’ issuance helped companies building 
strong reputations and market positioning (key strengths), generating larger companies, and 
consequently, higher market concentration. However, this position may be threatened with the 
105 Billion USD expected losses of exclusivity between 2018 and 2022 (IQVIA, 2018). 
The pharmaceutical markets are tailored towards addressing the population needs. In the US, 
19% is between the ages of 0 and 14 years old, 66% between 14 and 64, and 15% is above or 
equal to 65%. Life expectancy in the US is approximately 79 years old (World Bank, 2017). 
The most deadly diseases are heart disease, cancer, chronic obstructive pulmonary disease, 
accident, Alzheimer's disease (Medical News Today, 2017). The aging population is the 
fundamental source of pharmaceutical spending. In 2017, GDP per capita was 59,531.7 USD. 
Assuming a 1.5% annual growth rate of GDP per capita (equal to the one in 2017) (World Bank, 
2017), in 2022 GDP per capita is expected to be 64,132.55 USD. This means that, according to 
IQVIA 1.25% will be pharmaceutical spending. The high health insurance costs, aggravated by 
the increase in healthcare costs increase in comparison to insurance coverage (the deductible 
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cost increases more than the increase in insurance covered costs) (Deloitte, 2018), is the main 
challenge faced by patients in this country, particularly to low income families. This situation 
may worsen as, net price level is expected to rise 2-5% per year in the United States (IQVIA, 
2018). Companies face strict regulations, mainly concerning price (for instance, Affordable 
Care Act), and quality (controlled by the Food and Drug Administration). The regulations 
impose, however, are not deemed as enough. Ideas such as the increase in prices in foreign 
countries, the obligation to presents prices in ads, the elimination of insurance company 
intermediaries, and the faster generics approval, could be helpful to tailor protection towards 
patients, rather than just companies (Forbes, 2018). Advantages are given to financially 
sustainable companies and/ or that commercialize orphan drugs, which may be seen as a barrier 
of entry to new companies not able to match the early entrants results, contributing also to 
higher market concentration. The US market is highly dependent on the government (its main 
customer), leading to higher environmental volatility.  
In India, 28% of the total population is younger than 14 years old, 66% is between 14 and 64 
years old, and 6% is older than 64 years old. Life expectancy is approximately 69 years old 
(World Bank, 2017). The most deadly diseases are Heart Disease, Chronic Obstructive 
Pulmonary Disease, Stroke, and Diarrheal diseases (Institute for Health Metrics and Evaluation, 
2017). Some of the deadliest diseases are associated with poor sanitary conditions, such as lack 
of access to potable water. In 2017, GDP per capita was 1,939.6 USD (World Bank, 2017). 
Assuming a constant GDP per capita annual growth rate of 5.4% (equal to the one in 2017) 
GDP per capita is expected to be 2,522.99 USD in 2022. This means that, according to IQVIA 
0.991% will be spent in the pharmerging markets. According to Statista (2018) it is expected 
that by 2022 the GDP per capita will reach 2,803.49 USD, so higher than by assuming 5.4% 
growth rate. A higher GDP growth increases disposable income, leading to higher healthcare 
spending. Meanwhile, India is recognised for having lower R&D labour costs, production costs, 
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and R&D costs. The lower production costs, the focus on generics, and the lower market 
concentration are responsible for the lower prices of products commercialized. The rise 
accessibility and acceptability of generics, combined with the higher purchasing power are 
important growth factors for the Indian pharmaceutical market.  
The intense price competition and strict price regulations, although beneficial to patients, are 
deteriorating to the Indian companies' finances, particularly taking into consideration the 
presence of organised and disorganised players. If demand is not as elastic as the companies’ 
expect it to be a decrease in price may not lead to an increase in sales proportionally. This would 
mean a decrease in revenue, and therefore in gross sales margin, asset turnover and Return on 
Assets.  If on the other hand, the decrease in price leads to a disproportioned increase in demand 
companies’ may not be able to supply it while maintaining solid finances. This is mainly due 
to the lack of proper infrastructure, and investment in sales force, marketing and commercial 
operations. The lack of product quality recognition in international markets may also be a 
problem if little to no investment is made on increasing product awareness. As a result, the 
inefficient working capital management leads to liquidity issues, the depreciation of liquidity 
ratios, and possibly an increase in cash conversion cycle.  
Regarding market size, North America has the largest pharmaceutical drug market, being worth 
341.1 Billion USD and a market share of 36.5% share (Reportlinker, 2018). It US holds 33% 
of the total revenues in the global market and 45% of global sales (Statista, 2017) (position 
which has been stable since 2015). The US CAGR is expected to be 4.4%, 0.1% higher than 
the expected North America CAGR, from 2015 to 2020 (Deloitte, 2018). 
In 2015, emerging markets held 20% of global pharmaceutical sales. In 2017, they held 22% of 
global sales (Statista, 2017).  In 2017, India held around 1% of total revenue in the 
pharmaceuticals market (Statista, 2017). If there is an economic slowdown or price controls, 
and no specific strategy was to be adopted, the market would potentially only reach 35 Billion 
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USD in 2020 (CAGR=10%). On the other hand, in favourable conditions and aggressive 
growth, the market’s potential would be 70 Billion USD by 2020 (CAGR=17%). In 2020, the 
base scenario demonstrates that the Indian pharmaceuticals market is expected to reach 55 
Billion USD (CAGR=14.5%). It is expected to be ranking at the top, being close 2nd next to 
the US, in terms of volume. The combination between value and volume proves the market 
potential in terms of therapy and treatments provided. Hence, in either scenario, this market 
would still be able to perform higher CAGR than the expected for Asia & Australasia 
(CAGR=5%). This growth would be attributed 46% by acceptability (main driver), 20% by 
affordability, 33% by accessibility, and 1% by epidemiological factors (McKinsey, 2010). 
Annex 6: Conversion Rates at 31st March 
 USD INR 
31/03/2018 1.000 65.137 
31/03/2017 1.000 64.859 
31/03/2016 1.000 66.175 
31/03/2015 1.000 62.336 
31/03/2014 1.000 60.059 
31/03/2013 1.000 54.285 
 
Annex 7: Companies Website and SEC fillings 
Johnson & Johnson: https://www.jnj.com/about-jnj/annual-reports 
Pfizer: https://investors.pfizer.com/financials/sec-filings/default.aspx 
AbbVie: https://investors.abbvie.com/annual-report-proxy 
Merck & Co: https://investors.merck.com/financials/annual-reports-and-proxy/default.aspx 
Bristol-Myers Squibb: https://www.bms.com/investors/financial-reporting/annual-
reports.html 
Abbott Laboratories: https://www.abbottinvestor.com/financials/sec-filings 
Eli Lilly & Co: https://investor.lilly.com/financial-information/annual-reports 
Biogen: https://biogen.gcs-web.com/financials/annual-reports 
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Stryker Corporation: https://investors.stryker.com/financial-information/annual-
reports/default.aspx 
Regeneron Pharmaceuticals Inc.: https://newsroom.regeneron.com/financial-information 
Illumina: https://www.illumina.com/company/investor-information/financial-information/sec-
filings.html 
Mylan: http://investor.mylan.com/financial-information/sec-filings 
Alexion Pharmaceuticals: http://ir.alexion.com/financial-information/annual-reports 
BioMarin: https://investors.biomarin.com/sec-filings 
Incyte: https://investor.incyte.com/financial-information/sec-
filings?field_nir_sec_date_filed_value=&items_per_page=50&__aavo=17395084215315229
064#views-exposed-form-widget-sec-filings-table  
Sun Pharma: http://www.sunpharma.com/investors/annualreports\ 
Lupin Ltd.: https://www.lupin.com/investors/annual-reports/ 
Dr. Reddy's Laboratories: http://www.drreddys.com/investors/reports-and-filings/annual-
reports/ 
Cipla: https://www.cipla.com/en/investor-information/annual-reports.html 
Aurobindo Pharma: https://www.aurobindo.com/investors/results-reports-
presentations/annual-reports/ 
Zydus Cadila Healthcare: https://zyduscadila.com/financials 
Piramal Enterprises: http://www.piramal.com/investor/financial-reports/annual-reports 
Glenmark Pharmaceuticals: http://www.glenmarkpharma.com/investors/reports-presentation 
Torrent Pharmaceuticals: http://www.torrentpharma.com/Index.php/investors/index 
Biocon Ltd.: https://www.biocon.com/biocon_invrelation_annualreports.asp 
Ipca Laboratories: https://www.ipca.com/financials.html 
 
